Company intelligence / Profile preview
Hemay Pharmaceutical Technology
Ganzhou, Jiangxi, Chinahemaypharm.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Hemay has several small-molecule and biologic programs in mid-to-late clinical stages, including Mufemilast (PDE4 inhibitor) for inflammatory/autoimmune conditions in NDA/BLA stage and Sacibertinib (HER2 x Tyrosine kinase inhibitor) in Phase 3 for HER2+ breast cancer. Hemay808, a topical PDE4 inhibitor for atopic dermatitis, has completed Phase II trials in China. Some oncology programs (such as Hemay-020 targeting EGFR) faced trial terminations or are early-stage.
- Therapeutic areas
- OncologyImmunologyDermatologyPulmonologyRheumatologyGastroenterology
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Hemay Pharmaceutical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hemay Pharmaceutical Technology.